-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on Sutro Biopharma, Raises Price Target to $10

Benzinga·12/22/2025 11:54:10
Listen to the news
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with a Neutral and raises the price target from $2 to $10.